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Between November 2014 and May 2018, 118 labo-
ratory-confirmed cases of high-level azithromycin 
resistant  Neisseria gonorrhoeae  were identified in 
England. Cases emerged among heterosexuals in 
Leeds but spread across England and into sexual net-
works of men who have sex with men as the outbreak 
progressed. The few epidemiological links identified 
indicate substantial under-diagnosis of cases and this, 
along with the upturn in cases in 2017, highlights the 
difficulties in controlling the outbreak.
An outbreak of high-level azithromycin resist-
ant  Neisseria gonorrhoeae  (HL-AziR; minimum inhibi-
tory concentration (MIC) ≥ 256 mg/L) was first identified 
in Leeds in the north of England in 2015, where a local 
incident control team was convened [1-3]. This transi-
tioned into a national response in early 2016 as increas-
ing numbers of cases were identified in other parts of 
the country. The outbreak is still ongoing, despite a 
number of interventions, including increasing aware-
ness among clinicians and microbiologists, a national 
resistance alert issued by Public Health England (PHE) 
[4], and intensive follow-up of cases and their partners 
through partner notification (PN) by sexual health ser-
vices. This report provides an update on the epidemi-
ology of HL-AziR cases in England and describes the 
progression of the outbreak up to May 2018.
Description of the outbreak
Between November 2014 and May 2018, 118 laboratory 
confirmed cases of HL-AziR were identified in England. 
Despite concerns of rapid escalation and spread, the 
average number of new cases identified per month 
remained relatively stable initially, but cases per 
month increased from 2.6 in 2015 to 3.3 in 2017 and 
3.4 in 2018 (Figure 1). There was one reported treat-
ment failure in early 2018, but this infection was likely 
acquired outside of the United Kingdom (UK) [5,6]. This 
case was also the first global report of an isolate that 
had HL-AziR and was also resistant to ceftriaxone.
The outbreak emerged at the end of 2014 among young 
heterosexuals (median age 18 years, range 16–53; 
n = 15) living in deprived areas in Leeds. No specific 
risk factors, such as common educational establish-
ments, use of online dating applications (apps), or ven-
ues, were identified in the initial investigation. Most 
heterosexual cases were positive at a single site of 
infection (46/71), and were predominantly genital infec-
tions (41/50), among those where site of infection was 
known (Table 1). Re-attendance for test of cure among 
these cases was relatively low (10/15), even with inten-
sive follow-up of cases, and clinicians reported diffi-
culty in identifying partners.
Cases spread geographically (Figure 1A) and into sex-
ual networks of men who have sex with men (MSM) 
(Figure 1B) as the outbreak progressed. Cases among 
MSM were first identified in November 2015 mainly 
from a large, high-throughput clinic in London, which 
serves a substantial MSM population. Of the 36 cases 
identified among MSM, seven were known to be HIV-
positive (Table 1). MSM cases were generally older than 
heterosexual cases (median age 30 years, range 17–65) 
but also lived in deprived areas. Only a few MSM 
reported using apps or websites to meet sex partners, 
but this might be under-reported. Among MSM, most 
had a single site of infection (12/20), but the most com-
mon site of infection was pharyngeal (13/20) (Table 1). 
Re-attendance for test of cure was higher among MSM 
(31/36) compared with heterosexuals.
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Sexual partnerships and transmission 
networks
Six cases among MSM also exhibited bisexual behav-
iour suggesting a degree of fluidity between sexual 
networks, which may have facilitated more rapid 
and widespread transmission. Partner information 
was reported through enhanced surveillance for 82% 
(83/101) of cases up to December 2017 (52 hetero-
sexual and 31 MSM). The median number of partners 
in the previous 3 months reported per case was two 
among MSM (range 1–20 partners) and 1.5 among 
heterosexuals (range 1–11 partners). There were very 
few direct links identified between heterosexual cases 
(Figure 2A) and no direct links identified between any 
MSM cases (Figure 2B). Among 52 heterosexual cases, 
25 were epidemiologically linked to another case estab-
lishing 11 separate transmission networks (the largest 
linking four early Leeds cases).
Partner notification and case ascertainment
Effective PN is essential to controlling STI-related out-
breaks, but despite best efforts by clinic staff, success 
was limited. Only 35% (33/95) of partners reported 
Figure 1
Confirmed cases of high-level azithromycin resistant Neisseria gonorrhoeae by (A) area of residencea and (B) sexual 
orientation, England, November 2014 and May 2018 (n=118)
0
1
2
3
4
5
6
7
8
10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5
2015 2016 2017 2018
N
u
m
b
e
r 
o
f 
ca
s
e
s
Month and year of clinic visit
A.
B.
 
Male Gay
Male Bisexual
Male Heterosexual
Female Heterosexual
Male Unknown
Female Unknown
0
1
2
3
4
5
6
7
8
10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5
2015 2016 2017 2018
N
u
m
b
e
r 
o
f 
c
a
s
e
s
Month and year of clinic visit 
East Midlands East of England London
North East North West South East
West Midlands Yorkshire and the Humber South West
Data for end of May 2018 could be incomplete as there is a lag time of 2 to 3 weeks in antimicrobial susceptibility testing.
a Public Health England Centre.
3www.eurosurveillance.org
by heterosexual cases and 0% (0/153) of partners 
reported by MSM cases were verified by sexual health 
services as successfully contacted and tested (Table 
2). Among the partners who were tested, 14 of 29 were 
confirmed as new cases. Most of the reported partners 
were uncontactable because contact details were not 
disclosed by cases or were unavailable for casual part-
ners. In the absence of effective PN, high frequency of 
asymptomatic infection is likely to further contribute to 
sustained transmission; up to December 2017, 15 of 36 
MSM, 4 of 30 heterosexual men, and 18 of 35 women 
were asymptomatic (Table 1). Among the four linked 
heterosexual cases in Leeds, one became re-infected, 
further highlighting the potential impact of untreated 
partners on spread of the outbreak.
All cases were confirmed as high-level azithromycin 
resistant by PHE’s national reference laboratory. An esti-
mated 63% of all gonorrhoea diagnosed in England are 
cultured for antimicrobial susceptibility testing [7]. On 
multiple occasions, PHE attempted to improve the rate 
of referral of gonococcal isolates with suspected resist-
ance, identified by primary diagnostic laboratories to 
PHE’s national reference laboratory for confirmatory 
antimicrobial susceptibility testing. Referrals of gono-
coccal isolates with suspected azithromycin resistance 
increased from 34% (96/282) to 50% (219/437) and 
gonococcal isolates with suspected ceftriaxone resist-
ance increased from 27/89 isolates to 14/41 in 2015 and 
2017 (up to October), respectively, but remained sub-
optimal overall [8]. Issues related to low referrals rates 
by primary diagnostic laboratories included a lack of 
standard processes and staff awareness to ensure that 
isolates were referred, often exacerbated by high staff 
turn-over and difficulty with retrieval of cultures for 
transport to the national reference laboratory.
Discussion and conclusions
There has been sustained transmission of HL-AziR in 
England since November 2014. Few cases had identified 
epidemiological links and this, along with the limited 
effectiveness of PN, suggests there is likely a con-
siderable reservoir of undiagnosed infection fuelling 
transmission. Despite the lack of direct links identified 
between most cases, the early geographic clustering, 
and multiple bisexual cases potentially linking hetero-
sexual and MSM sexual networks, strongly suggested 
Table 1a
Characteristics and demographics of laboratory-confirmed cases of high-level azithromycin resistant Neisseria gonorrhoeae, 
England November 2014 ‒May 2018
Patient characteristics Women Heterosexual Men MSM Men unknown Total
n (col %)
Total cases (n) 41 (100) 30 (100) 36 (100) 11 (100) 118 (100)
Ethnicity
White 31 (76) 19 (63) 24 (67) 0 (0) 74 (63)
Black 0 (0) 5 (17) 6 (17) 0 (0) 11 (9)
Other 2 (5) 5 (17) 6 (17) 0 (0) 13 (11)
Unknown 8 (20) 1 (3) 0 (0) 11 (100) 20 (17)
Age group (years)
15–19 21 (51) 9 (30) 4 (11) 1 (9) 35 (30)
20–24 14 (34) 8 (27) 6 (17) 2 (18) 30 (25)
25–34 5 (12) 8 (27) 14 (39) 5 (45) 32 (27)
≥ 35 1 (2) 5 (17) 12 (33) 3 (27) 21 (18)
Yes 28 (68) 24 (80) 24 (67) 0 (0) 76 (64)
No 2 (5) 3 10() 11 (31) 0 (0) 16 (14)
Unknown 11 (27) 3 (10) 1 (3) 11 (100) 26 (22)
World region of birth
UK 28 (72) 24 (80) 24 (67) 0 (0) 76 (68)
Other 2 (5) 3 (10) 11 (31) 0 (0) 16 (14)
Unknown 9 (23) 3 (10) 1 (3) 6 (100) 19 (17)
HIV status
Positive 0 (0) 0 (0) 7 (19) 0 (0) 7 (6)
Negative/Undiagnosed 27 (66) 25 (83) 27 (75) 0 (0) 79 (67)
Unknown 14 (34) 5 (17) 2 (6) 11 (0) 32 (27)
Index of multiple deprivation
Most deprived 13 (32) 11 (37) 7 (19) 0 (0) 31 (26)
2nd most deprived 5 (12) 2 (7) 16 (44) 0 (0) 23 (19)
3rd most deprived 2 (5) 2 (7) 7 (19) 0 (0) 11 (9)
4th most deprived 2 (5) 5 (17) 3 (8) 0 (0) 10 (8)
Least deprived 4 (10) 3 (10) 1 (3) 0 (0) 8 (7)
Unknown 15 (37) 7 (23) 2 (6) 11 (100) 35 (30)
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these cases belonged to a discrete outbreak, which 
was confirmed by whole genome sequencing (WGS) 
[9]. WGS of isolates up to February 2017 demonstrated 
that most of the cases shared a distant common ances-
tor, and 37 of 60 cases were genetically similar (clonal) 
[9].
The HL-AziR clonal spread among initial outbreak cases 
in Leeds [9] may have been facilitated by an identi-
fied sexual network including four cases, one of whom 
also became re-infected and indicated ongoing trans-
mission over several months. A local outbreak control 
team was convened and the last case was identified 
in October 2015. A brief resurgence of cases in Leeds 
in 2016 (one case diagnosed in June and then three 
cases in October and November) were not identified 
as having epidemiological links to the initial outbreak 
cases. WGS demonstrated that the isolates from the 
later cases had evolved, but were still closely related, 
Table 1b
Characteristics and demographics of laboratory-confirmed cases of high-level azithromycin resistant Neisseria gonorrhoeae, 
England November 2014 ‒May 2018
Source: GUMCAD STI Surveillance System and enhanced surveillance of cases. STI: sexually transmitted infection; UK: United Kingdom.
a Data from enhanced surveillance on all cases up to March 2017 only (n = 71).
b Abbreviated enhanced surveillance only for cases April to December 2017 (n = 30).
c Patients may not have been tested for all sites.
d Refers to sex on premises, venues including saunas and sex clubs.
Patient characteristics Women Heterosexual Men MSM Men unknown Total
n (col %)
Enhanced data on cases (n)a 35 (100) 30 (100) 36 (100) 0 (100) 101 (100)
Symptomsb
Discharge and/or Dysuria 13 (37) 25 (83) 19 (53) 0 57 (56)
No Discharge and/or Dysuria 18 (51) 4 (13) 15 (42) 0 37 (37)
Unknown 4 (11) 1 (3) 2 (6) 0 7 (7)
Site(s) positiveb,c
Genital 21 (60) 25 (83) 9 (25) 0 55 (54)
Rectal 5 (14) 0 (0) 8 (22) 0 13 (13)
Throat 7 (20) 1 (3) 13 (36) 0 21 (21)
Other 1 (3) 1(3) 0 (0) 0 2 (2)
Unknown sites 11(31) 4 (13) 16 (44) 0 31 (31)
Multiple/single site(s) b,c
Single site 16 (46) 25 (83) 12 (33) 0 53 (53)
Multiple sites 8 (23) 1 (3) 8 (22) 0 17 (17)
Unknown sites 11(31) 4 (13) 16 (44) 0 31 (31)
Test of cure
Yes 20 (57) 18 (60) 31 (86) 0 69 (68)
No 11 (31) 11 (37) 4 (11) 0 26 (26)
Unknown 4 (11) 1 (3) 1 (3) 0 6 (6)
Partners (past 3 months)
0–1 14 (40) 12 (40) 6 (17) 0 32 (32)
2–5 11 (31) 14 (47) 16 (44) 0 41 (40)
6–10 0 (0) 0 (0) 6 (17) 0 6 (6)
11 + 0 (0) 1 (3) 3 (8) 0 4 (4)
Unknown 10 (29) 3 (10) 5 (14) 0 18 (18)
Venues (past month)d
Yes 0 (0) 0 (0) 3 (8) 0 3 (3)
No 0 (0) 0 (0) 1 (3) 0 1 (1)
Unknown 35 (100) 30 (100) 32 (89) 0 97 (96)
Websites (past month)
Yes 0 (0) 0 (0) 2 (6) 0 2 (2)
No 0 (0) 0 (0) 3 (8) 0 3 (3)
Unknown 35 (100) 30 (100) 31 (86) 0 96 (95)
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genetically [9]. This suggests that even with the decline 
in cases in Leeds, the strain continued to circulate.
Gonorrhoea treatment guidelines published by the 
World Health Organisation (WHO), the UK, Europe and 
many other countries recommend first-line dual therapy 
with ceftriaxone and azithromycin to treat gonorrhoea 
[10,11] in an attempt to delay the development of resist-
ance to ceftriaxone, which despite sporadic reports, 
remains rare [12-17]. While low-level azithromycin 
resistance (0.5 mg/L < MIC < 256 mg/L) in gonorrhoea is 
increasing in many countries [18], HL-AziR cases have 
previously been uncommon or have belonged to small 
contained outbreaks [19,20], suggesting that HL-AziR 
may lead to a fitness cost. The data presented here 
tend not to support this view, although information on 
population-wide transmission dynamics of different 
gonococcal strains is sparse [21].
The outbreak received substantial national and local 
media attention, and multiple communications aimed 
at providing advice and improving awareness among 
primary diagnostic laboratories and sexual health 
services were undertaken. However, the limited effec-
tiveness of PN and poor re-attendance for test of cure, 
even with intense follow-up, severely hampered control 
efforts. Referral of suspected azithromycin-resistant 
gonococcal isolates by primary diagnostic laboratories 
for confirmatory testing by PHE’s national reference 
laboratory remains sub-optimal.
The increase in HL-AziR cases during 2017, predomi-
nantly in MSM in London, demonstrates how an out-
break of gonorrhoea can spread geographically, and 
within and between sexual networks, even with inten-
sive interventions in place. The outbreak highlights the 
potential for rapid transmission of highly resistant or 
even untreatable strains of gonorrhoea in the future. 
Figure 2
Partner network diagram of laboratory confirmed cases of high-level azithromycin resistant Neisseria gonorrhoeae and 
their reported partners by (A) heterosexual and (B) men who have sex with men (MSM) cases, England, November 2014 to 
December 2017 (n = 324)
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Research to identify effective approaches to encour-
age and empower people to get tested for STIs and to 
identify barriers to accessing healthcare are urgently 
required in order to implement unified, enhanced strat-
egies in the prevention of gonorrhoea.
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